{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T20:22:53Z","timestamp":1648758173066},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"29","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1097\/md.0000000000004237","type":"journal-article","created":{"date-parts":[[2016,7,20]],"date-time":"2016-07-20T16:09:13Z","timestamp":1469030953000},"page":"e4237","source":"Crossref","is-referenced-by-count":1,"title":["Lymphoma in Danon disease with chronic rhabdomyolysis treated with EPOCH-R"],"prefix":"10.1097","volume":"95","author":[{"given":"Edit","family":"Porpaczy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marius","family":"Mayerhoefer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Salzer-Muhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Jaeger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-19-20210309","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1161\/CIRCHEARTFAILURE.114.001105","article-title":"Danon disease: clinical features, evaluation, and management","volume":"7","author":"D'Souza","year":"2014","journal-title":"Circ Heart Fail"},{"key":"R2-19-20210309","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1212\/WNL.31.1.51","article-title":"Lysosomal glycogen storage disease with normal acid maltase","volume":"31","author":"Danon","year":"1981","journal-title":"Neurology"},{"key":"R3-19-20210309","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/35022604","article-title":"Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease)","volume":"406","author":"Nishino","year":"2000","journal-title":"Nature"},{"key":"R4-19-20210309","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1470-2045(11)70300-X","article-title":"Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial","volume":"13","author":"Trappe","year":"2012","journal-title":"Lancet Oncol"},{"key":"R5-19-20210309","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11899-013-0162-5","article-title":"Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies","volume":"8","author":"Al-Mansour","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"R6-19-20210309","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.2165\/11635690-000000000-00000","article-title":"Managing post-transplant lymphoproliferative disorders in solid-organ transplant recipients: a review of immunosuppressant regimens","volume":"72","author":"Murukesan","year":"2012","journal-title":"Drugs"},{"key":"R7-19-20210309","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1365-2141.2010.08160.x","article-title":"Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients: BCSH and BTS guidelines","volume":"149","author":"Parker","year":"2010","journal-title":"Br J Haematol"},{"key":"R8-19-20210309","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/978-3-319-13150-4_13","article-title":"Post-transplant lymphoproliferative disorders","volume":"165","author":"Singavi","year":"2015","journal-title":"Cancer Treat Res"},{"key":"R9-19-20210309","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1007\/s10545-009-1097-9","article-title":"Danon disease: case report and detection of new mutation","volume":"32","author":"Regelsberger","year":"2009","journal-title":"J Inherit Metab Dis"},{"key":"R10-19-20210309","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s11864-011-0177-x","article-title":"Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations","volume":"13","author":"Jagadeesh","year":"2012","journal-title":"Curr Treat Options Oncol"},{"key":"R11-19-20210309","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","article-title":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","volume":"368","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med"},{"key":"R12-19-20210309","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjh.13463","article-title":"Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis","volume":"170","author":"Howlett","year":"2015","journal-title":"Br J Haematol"},{"key":"R13-19-20210309","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1186\/s12885-015-1407-6","article-title":"The prevention, detection and management of cancer treatment-induced cardiotoxicity: a meta-review","volume":"15","author":"Conway","year":"2015","journal-title":"BMC Cancer"},{"key":"R14-19-20210309","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s13105-012-0200-0","article-title":"Tissue retention of doxorubicin and its effects on cardiac, smooth, and skeletal muscle function","volume":"69","author":"Hayward","year":"2013","journal-title":"J Physiol Biochem"},{"key":"R15-19-20210309","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nrneurol.2013.163","article-title":"Lysosomal storage diseases: the horizon expands","volume":"9","author":"Boustany","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"R16-19-20210309","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.biochi.2015.11.009","article-title":"Glucosylceramidases and malignancies in mammals","volume":"125","author":"Astudillo","year":"2016","journal-title":"Biochimie"},{"key":"R17-19-20210309","doi-asserted-by":"crossref","first-page":"878","DOI":"10.5966\/sctm.2014-0213","article-title":"Gaucher disease-induced pluripotent stem cells display decreased erythroid potential and aberrant myelopoiesis","volume":"4","author":"Sgambato","year":"2015","journal-title":"Stem Cells Transl Med"},{"key":"R18-19-20210309","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1097\/00007890-199812270-00035","article-title":"Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants","volume":"66","author":"Davis","year":"1998","journal-title":"Transplantation"},{"key":"R19-19-20210309","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1182\/blood.V124.21.4449.4449","article-title":"The impact of immunophenotypic subtypes and treatment regimens on patient outcomes in monomorphic post-transplant lymphoproliferative disorders (diffuse large B-cell lymphoma)","volume":"124","author":"Radeski","year":"2014","journal-title":"Blood"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000004237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:28:59Z","timestamp":1620959339000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201607190-00019"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":19,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000004237","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]}}}